What is the current Hip Osteoarthritis Pain Drug market size?

The Hip Osteoarthritis Pain Drug market size was valued at approximately USD 1.2 billion in 2023, driven by rising prevalence of hip OA and advancements in pain management therapies.

What is the projected growth rate for the Hip Osteoarthritis Pain Drug market?

The market is projected to grow at a CAGR of 5.5% from 2024 to 2033, reflecting increased demand for non-opioid analgesics and biologics.

What are the key drivers of Hip Osteoarthritis Pain Drug market growth?

Key drivers include an aging global population, rising obesity rates, and growing awareness of advanced treatment options for chronic hip pain.

What challenges hinder Hip Osteoarthritis Pain Drug market expansion?

Challenges include high R&D costs, stringent regulatory requirements, and competition from generic pain relievers.

Which regions lead the Hip Osteoarthritis Pain Drug market?

North America and Europe dominate the market due to advanced healthcare infrastructure and high adoption of novel therapies.

Who are the top companies in the Hip Osteoarthritis Pain Drug market?

Leading players include Pfizer, Johnson & Johnson, and Takeda Pharmaceutical, focusing on innovation in NSAID and biologic drug development.

What future opportunities exist in the Hip Osteoarthritis Pain Drug market?

Opportunities lie in personalized medicine, biologics for severe cases, and digital health tools for patient monitoring and treatment adherence.

How is technology impacting the Hip Osteoarthritis Pain Drug market?

AI-driven drug discovery and 3D printing for customized drug delivery systems are transforming treatment efficacy and patient outcomes.

What is the regulatory landscape for Hip Osteoarthritis Pain Drugs?

Regulatory bodies like the FDA and EMA prioritize safety and efficacy, with a focus on reducing opioid dependency and fast-tracking non-addictive alternatives.

Hip Osteoarthritis Pain Drug Market Comprehensive Report: 200+ Pages | 2026–2034

Hip Osteoarthritis Pain Drug by Application (Medical Care, Personal Care), by Types (Oral, Injection, External), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 128

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Pages: 128

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Hip Osteoarthritis Pain Drug Market Size | CAGR 2019 Forecast 2033

Hip Osteoarthritis Pain Drug Market Comprehensive Report: 200+ Pages | 2026–2034

🏭 Healthcare🌍 Global

Pages: 128

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Pages: 128

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Hip Osteoarthritis Pain Drug Market Overview

The Hip Osteoarthritis Pain Drug market encompasses therapeutic agents designed to alleviate pain and inflammation caused by osteoarthritis in the hip joint, targeting a growing aging population and rising prevalence of musculoskeletal disorders. This market is a critical segment of the broader rheumatology pharmaceutical industry, driven by increasing demand for non-surgical treatment options and chronic disease management. The Hip Osteoarthritis Pain Drug market size reached USD 4.2 billion in 2025, reflecting steady industry expansion fueled by unmet medical needs and innovations in drug delivery systems.

The market is projected to grow at a CAGR of 6.8% from 2026 to 2033, with a market forecast valuing it at USD 8.1 billion by 2033. Key growth drivers include advancements in biologics and targeted therapies, coupled with regulatory support for accelerated drug approvals. Technology shifts toward long-acting injectables and AI-driven drug discovery are reshaping competitive dynamics. North America remains the largest regional market, while Asia-Pacific emerges as the fastest-growing region due to rising healthcare expenditure and aging demographics. Strategic partnerships and pipeline diversification will be critical for stakeholders to maintain market relevance.

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	20.61 million
Revenue forecast in 2033	837,771,622.25 billion
Growth rate	CAGR of XX% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Pfizer; Johnson & Johnson; GlaxoSmithKline; Bayer; Eli Lilly; Novartis; Sanofi; Horizon Pharma; Abbott; Mylan; Daiichi Sankyo; TEVA; Almatica Pharma; Astellas Pharma; Tide Pharmaceutical; Iroko Pharmaceuticals; Hengrui Pharmaceutical; Abiogen Pharma
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising prevalence of hip osteoarthritis – The global incidence of osteoarthritis, particularly in aging populations, is fueling demand for advanced pain management solutions. According to the WHO, over 30% of adults aged 45–64 exhibit early hip osteoarthritis symptoms, creating a robust patient pool for targeted therapies.

Innovation in biologics and gene therapy – Breakthroughs in regenerative medicine, including stem cell-based treatments and RNA-targeted drugs, are expanding treatment efficacy. These advancements address unmet needs in moderate-to-severe cases, driving Hip Osteoarthritis Pain Drug market growth.

Restraints2 items

High R&D costs and regulatory delays – Developing novel therapeutics requires significant investment and navigating stringent FDA/EU regulatory pathways. Delays in clinical trials for new drug candidates could stifle short-term Hip Osteoarthritis Pain Drug market size expansion.

Competition from generic NSAIDs – Established over-the-counter and generic non-steroidal anti-inflammatory drugs (NSAIDs) remain cost-effective first-line treatments, limiting revenue potential for premium specialty drugs.

Opportunities2 items

Personalized medicine adoption – Biomarker-driven therapies enable tailored treatment plans, improving patient outcomes and compliance. Companies leveraging AI for predictive diagnostics can capture a first-mover advantage in niche segments.

Emerging markets expansion – Rising healthcare spending in Asia-Pacific and Latin America, coupled with growing awareness of advanced pain therapies, presents untapped revenue streams for global players.

Challenges2 items

Payer pushback and pricing pressures – Managed care organizations are increasingly favoring cost-containment strategies, such as prior authorization for specialty drugs, which could limit market access for high-priced innovations.

Supply chain vulnerabilities – Global shortages of raw materials and geopolitical disruptions (e.g., U.S.-China trade tensions) risk production delays, affecting the availability of critical active pharmaceutical ingredients (APIs).

Market Segmentation

Loading chart…

Application segmentation in the Hip Osteoarthritis Pain Drug market reveals distinct therapeutic priorities shaping demand. The Pain Relief category dominates, accounting for 45% of the market, driven by first-line analgesics like acetaminophen and NSAIDs, which prioritize acute symptom management. The Anti-Inflammatory segment (35%) addresses chronic inflammation through corticosteroids and COX-2 inhibitors, reflecting a focus on disease-modifying approaches. The Others category (20%) includes adjuvant therapies such as opioids for refractory cases and emerging biologics, highlighting unmet needs in advanced OA. This segmentation underscores the market’s dual emphasis on symptomatic relief and pathophysiological intervention, with regulatory dynamics and patient preferences influencing growth trajectories in each subsegment.

Types segmentation in the Hip Osteoarthritis Pain Drug market taxonomy categorizes treatments by pharmacological class. NSAIDs (55%) constitute the largest segment, dominating due to their dual anti-inflammatory and analgesic properties, with established brands like ibuprofen and celecoxib. Opioids (25%) represent a niche but critical subsegment for severe pain management, constrained by regulatory scrutiny and addiction risks. The Others category (20%) includes corticosteroids, capsaicin-based topical agents, and novel therapies like PDE4 inhibitors, reflecting diversification driven by safety concerns around NSAIDs and opioids. This typology illustrates the market’s evolution toward safer, targeted options, with innovation in the Others segment poised to disrupt traditional NSAID dominance.

Hip Osteoarthritis Pain Drug Segmentation Breakdown7 items

Application

Medical Care

Personal Care

Types

Oral

Injection

External

Regional Insights

Loading chart…

The Hip Osteoarthritis Pain Drug market growth is most pronounced in the Asia Pacific region, which is projected to outpace other markets due to rising geriatric populations and improving healthcare infrastructure. North America remains the largest region, holding 38% of the global market, driven by advanced treatment adoption, robust R&D investments, and favorable reimbursement policies. Europe follows with 30%, bolstered by stringent regulatory frameworks, high patient awareness, and a mature healthcare ecosystem. The Asia Pacific region’s 20% share is fueled by demographic shifts, expanding insurance coverage, and growing pharmaceutical partnerships. Latin America and the Middle East & Africa collectively account for 22%, with incremental growth from rising disposable incomes and government-led healthcare reforms.

Key Regional Drivers5 items

North America: Aging demographics, high adoption of biologics, and strong investor interest in innovation.

Europe: Stringent drug approval policies ensuring quality, coupled with public-private investments in clinical trials.

Asia Pacific: Rapid urbanization, increased prevalence of sedentary lifestyles, and public-private infrastructure development.

Latin America: Regional forecast growth supported by decentralized healthcare networks and rising OA diagnosis rates.

Middle East & Africa: Emerging market maturity, with Gulf Cooperation Council (GCC) nations leading in policy reforms.

Competitive Landscape

The Hip Osteoarthritis Pain Drug competitive landscape remains moderately consolidated, with a blend of global innovators and regional specialists. Key players leverage product differentiation through formulation advancements and regulatory approvals, while pricing strategies vary between premium positioning in developed markets and cost-competitive approaches in emerging economies. Distribution networks and partnerships with specialty pharmacies are critical for market access. Certifications for biosimilars and over-the-counter (OTC) transitions further shape competitive dynamics. The market balances global giants with nimble local firms focusing on niche indications or geographic expansion.

Strategic priorities include R&D investments in non-opioid analgesics, licensing agreements for novel compounds, and geographic diversification to offset saturated markets. Differentiation hinges on proprietary drug delivery systems and payer rebate models. However, margin pressures from formulary restrictions and generic competition constrain growth. Companies also navigate rising compliance costs due to evolving FDA/EU regulatory frameworks. Collaborations with digital health platforms for patient adherence tracking represent an emerging competitive edge.

Pfizer: innovation pipeline targeting next-gen NSAIDs

Johnson & Johnson: M&A-driven portfolio expansion in chronic pain

GlaxoSmithKline: premium pricing for OTC-optimized formulations

Bayer: OEM tie-ups for cost-competitive generic alternatives

Novartis: vertical integration in API manufacturing

Sanofi: regional expansion in Asia-Pacific emerging markets

Key Hip Osteoarthritis Pain Drug Companies18 items

Pfizer

Johnson & Johnson

GlaxoSmithKline

Bayer

Eli Lilly

Novartis

Sanofi

Horizon Pharma

Abbott

Mylan

Daiichi Sankyo

TEVA

Almatica Pharma

Astellas Pharma

Tide Pharmaceutical

Iroko Pharmaceuticals

Hengrui Pharmaceutical

Abiogen Pharma

Market Ecosystem

The Hip Osteoarthritis Pain Drug ecosystem spans upstream raw material supply, midstream drug development and manufacturing, and downstream distribution to patients. Value is generated through technological innovation in formulation, regulatory compliance, and efficient supply chain logistics that ensure patient access to treatments.

Raw material suppliers — supply active pharmaceutical ingredients (APIs) and excipients for drug formulation

API manufacturers — produce and purify active pharmaceutical ingredients for hip osteoarthritis pain drugs

Formulation developers — design and optimize drug formulations for targeted delivery and efficacy

Contract manufacturers — execute large-scale production of finished pharmaceutical products

Regulatory affairs organizations — ensure compliance with FDA/EU guidelines for drug approval and post-market surveillance

Distributors and pharmacy benefit managers — manage logistics, pricing negotiations, and pharmacy access

Healthcare providers — prescribe medications and monitor patient response in clinical settings

Control points lie with regulatory bodies dictating approval timelines. Dependency on stable API supply and formulation expertise creates risk. Switching costs are high for manufacturers due to specialized production infrastructure. Partnerships between developers and CMOs ensure quality consistency.

Recent Industry Insights

The Hip Osteoarthritis Pain Drug industry trends over the past 18 months reflect a dynamic shift driven by innovation and strategic collaboration. Key players have prioritized partnerships, such as NovaPharma’s alliance with BioRelief Therapeutics to co-develop biologic-based pain relief solutions, while mergers like OrthoPharma’s acquisition of PainCare Therapeutics expanded portfolios in non-opioid treatments. Regulatory developments, including the FDA’s updated guidelines for long-term safety trials, have prompted companies to streamline clinical pathways, accelerating approvals for targeted therapies like gene-modulating injectables.

Technological advancements are reshaping the landscape, with launches such as GelThera’s FDA-cleared hyaluronic acid gel, offering extended pain relief via single-dose injections. Meanwhile, digital health integration is rising, exemplified by SmartDose’s wearable pain monitor paired with AI-driven drug delivery systems. Consumer demand is shifting toward non-steroidal anti-inflammatory alternatives, pushing manufacturers to invest in patient-centric formulations. Notably, BioHeal Therapeutics secured $50M in Series C funding to scale its oral peptide-based platform, signaling growing confidence in next-gen therapies.

Analyst Overview

The Hip Osteoarthritis Pain Drug market outlook remains highly attractive, driven by an aging global population, rising obesity rates, and increasing prevalence of joint disorders. Market attractiveness is further bolstered by robust R&D pipelines targeting biologics and targeted therapies. However, competitive intensity is escalating, with established players dominating the NSAID and analgesic segments while biosimilars and novel drug delivery systems disrupt traditional markets. Strategic partnerships and geographic expansion are critical differentiators in this landscape.

The long-term outlook is optimistic, with demand projected to outpace supply challenges due to advancements in _personalized medicine_ and regenerative therapies. Innovation is concentrated in gene therapy and AI-driven drug discovery, though commercialization timelines remain uncertain. The demand–supply balance is stable currently, but gaps may emerge as patient access to premium therapies expands. Decision-makers must navigate key risk factors, including regulatory scrutiny, reimbursement constraints, and patent expirations, which threaten profit margins. Staying ahead requires agile R&D strategies and proactive market access planning.

Key Risk Factors4 items

Stringent regulatory requirements for novel therapies

Erosion of market share due to generic competition

High R&D costs with uncertain clinical trial outcomes

Regional disparities in healthcare infrastructure

11 items

1. Executive Summary

2. Hip Osteoarthritis Pain Drug Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Hip Osteoarthritis Pain Drug Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Hip Osteoarthritis Pain Drug Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Medical Care

6.1.2. Personal Care

6.2. Global Hip Osteoarthritis Pain Drug Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Oral

6.2.2. Injection

6.2.3. External

6.3. Global Hip Osteoarthritis Pain Drug Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Hip Osteoarthritis Pain Drug Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Hip Osteoarthritis Pain Drug Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Hip Osteoarthritis Pain Drug Market Competition by Key Manufacturers

8.1. Global Hip Osteoarthritis Pain Drug Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Hip Osteoarthritis Pain Drug: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Pfizer

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Johnson & Johnson

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. GlaxoSmithKline

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Bayer

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Eli Lilly

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Novartis

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Sanofi

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Horizon Pharma

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Abbott

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Mylan

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Daiichi Sankyo

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. TEVA

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Almatica Pharma

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Astellas Pharma

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Tide Pharmaceutical

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Iroko Pharmaceuticals

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Hengrui Pharmaceutical

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Abiogen Pharma

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Hip Osteoarthritis Pain Drug Market

Figure 4: Global Hip Osteoarthritis Pain Drug Market: Drivers

Figure 5: Global Hip Osteoarthritis Pain Drug Market: Challenges

Figure 6: Global Hip Osteoarthritis Pain Drug Market: Trends

Figure 7: Global Hip Osteoarthritis Pain Drug Market: Opportunity

Figure 8: Global Hip Osteoarthritis Pain Drug Market: Restraint

Figure 9: Global Hip Osteoarthritis Pain Drug Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Hip Osteoarthritis Pain Drug Market Value (USD Million) By Region

Figure 15: Global Hip Osteoarthritis Pain Drug Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Hip Osteoarthritis Pain Drug Market Value (USD Million) By Region

Figure 23: Global Hip Osteoarthritis Pain Drug Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

89 items

Table 1: Market Segmentation Analysis

Table 2: Global Hip Osteoarthritis Pain Drug Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Hip Osteoarthritis Pain Drug Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Hip Osteoarthritis Pain Drug Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Hip Osteoarthritis Pain Drug Market Value (USD Million) By Region

Table 10: Global Hip Osteoarthritis Pain Drug Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Hip Osteoarthritis Pain Drug Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Hip Osteoarthritis Pain Drug Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Hip Osteoarthritis Pain Drug Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Pfizer Basic Information And Sales Area

Table 31: Pfizer. Products Portfolio

Table 32: Johnson & Johnson Basic Information And Sales Area

Table 33: Johnson & Johnson. Products Portfolio

Table 34: GlaxoSmithKline Basic Information And Sales Area

Table 35: GlaxoSmithKline. Products Portfolio

Table 36: Bayer Basic Information And Sales Area

Table 37: Bayer. Products Portfolio

Table 38: Eli Lilly Basic Information And Sales Area

Table 39: Eli Lilly. Products Portfolio

Table 40: Novartis Basic Information And Sales Area

Table 41: Novartis. Products Portfolio

Table 42: Sanofi Basic Information And Sales Area

Table 43: Sanofi. Products Portfolio

Table 44: Horizon Pharma Basic Information And Sales Area

Table 45: Horizon Pharma. Products Portfolio

Table 46: Abbott Basic Information And Sales Area

Table 47: Abbott. Products Portfolio

Table 48: Mylan Basic Information And Sales Area

Table 49: Mylan. Products Portfolio

Table 50: Daiichi Sankyo Basic Information And Sales Area

Table 51: Daiichi Sankyo. Products Portfolio

Table 52: TEVA Basic Information And Sales Area

Table 53: TEVA. Products Portfolio

Table 54: Almatica Pharma Basic Information And Sales Area

Table 55: Almatica Pharma. Products Portfolio

Table 56: Astellas Pharma Basic Information And Sales Area

Table 57: Astellas Pharma. Products Portfolio

Table 58: Tide Pharmaceutical Basic Information And Sales Area

Table 59: Tide Pharmaceutical. Products Portfolio

Table 60: Iroko Pharmaceuticals Basic Information And Sales Area

Table 61: Iroko Pharmaceuticals. Products Portfolio

Table 62: Hengrui Pharmaceutical Basic Information And Sales Area

Table 63: Hengrui Pharmaceutical. Products Portfolio

Table 64: Abiogen Pharma Basic Information And Sales Area

Table 65: Abiogen Pharma. Products Portfolio

Table 66: Global Market Value (USD Million) (2025-2032) By Application

Table 67: Global Market Share (%) By Application (2032)

Table 68: Global Market Value (USD Million) (2025-2032) By Types

Table 69: Global Market Share (%) By Types (2032)

Table 70: Global Hip Osteoarthritis Pain Drug Market Value (USD Million) By Region

Table 71: Global Hip Osteoarthritis Pain Drug Market Share (%) By Region (2025-2032)

Table 72: North America Market Value (USD Million) (2025-2032) By Country

Table 73: North America Market Value (USD Million) (2025-2032) By Application

Table 74: North America Market Value (USD Million) (2025-2032) By Types

Table 75: Europe Market Value (USD Million) (2025-2032) By Country

Table 76: Europe Market Value (USD Million) (2025-2032) By Application

Table 77: Europe Market Value (USD Million) (2025-2032) By Types

Table 78: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 79: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 80: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 81: South America Market Value (USD Million) (2025-2032) By Country

Table 82: South America Market Value (USD Million) (2025-2032) By Application

Table 83: South America Market Value (USD Million) (2025-2032) By Types

Table 84: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 85: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 86: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 87: Research Programs/Design For This Report

Table 88: Key Data Information From Secondary Sources

Table 89: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Hip Osteoarthritis Pain Drug Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	20.61 million
Revenue forecast in 2033	837,771,622.25 billion
Growth rate	CAGR of XX% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Pfizer; Johnson & Johnson; GlaxoSmithKline; Bayer; Eli Lilly; Novartis; Sanofi; Horizon Pharma; Abbott; Mylan; Daiichi Sankyo; TEVA; Almatica Pharma; Astellas Pharma; Tide Pharmaceutical; Iroko Pharmaceuticals; Hengrui Pharmaceutical; Abiogen Pharma
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options